ESR1 and breast carcinoma: For example, tamoxifen, which is an antagonist of the estrogen receptor, and trastuzumab, which is a monoclonal antibody that acts on the HER2 receptor, have improved the survival outcome of luminal and HER2 breast cancer subtypes, respectively.